Chase Investment Counsel Corp Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX

Chase Investment Counsel Corp acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,885,000.

Other institutional investors have also recently modified their holdings of the company. Parkside Financial Bank & Trust grew its holdings in Catalyst Pharmaceuticals by 17.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 469 shares during the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of Catalyst Pharmaceuticals by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 472 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 4.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 474 shares in the last quarter. Lifestyle Asset Management Inc. lifted its position in shares of Catalyst Pharmaceuticals by 3.4% in the fourth quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 553 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on CPRX shares. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $31.49 on Monday. The firm has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. The stock’s 50-day moving average price is $31.45 and its two-hundred day moving average price is $28.21. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).